Microbot Medical Receives Intention to Grant from European Patent Office for a Patent Application Covering its Self-Cleaning ...
January 08 2020 - 7:00AM
Microbot Medical Inc. (Nasdaq: MBOT) has received an official
communication from the European Patent Office (EPO) regarding its
intention to grant European Patent Application No. 11795301,
covering the Company’s Self-Cleaning Shunt (SCS™). Globally, the
Company now has 36 patents issued/allowed and 16 patent
applications pending worldwide.
“We have always maintained that a strong and
growing intellectual property portfolio is one of our strongest
assets and will enable us to maintain a sustainable
competitive advantage while establishing barriers of entry to
future competitors” said Harel Gadot, Chief Executive Officer,
President, and Chairman. “We will continue to expand and seek
protection for our unique innovative platforms. This provides the
foundation for the establishment of a multi-generation product
portfolio, including our latest introduction of the
LIBERTY™ Robotic System, the world’s first fully disposable
robotic system for use in neurovascular, cardiovascular and
peripheral vascular procedures.”
The allowed patent application covers an inlet
head for use on shunts, such as Ventriculoperitoneal (VP) Shunts
which are implanted in Hydrocephalus patients for draining excess
cerebrospinal fluid (CSF). The inlet head includes a tube with
openings disposed in its wall, and a cleaning element comprising a
central shaft with protruding bristles installed inside the tube,
such that mutual vibratory motion between the cleaning element and
the tube causes the bristles to move within the openings. Such
movement maintains the openings clear and thereby prevents shunt
occlusion.
Click to tweet link: https://ctt.ac/9DV2b
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a
pre-clinical medical device company that specializes in
transformational micro-robotic technologies, focused primarily on
both natural and artificial lumens within the human body.
Microbot’s current proprietary technological platforms provide the
foundation for the development of a Multi Generation Pipeline
Portfolio (MGPP).
Microbot Medical was founded in 2010 by Harel
Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of
improving clinical outcomes for patients and increasing
accessibility through the use of micro-robotic technologies.
Further information about Microbot Medical is available at
http://www.microbotmedical.com.
Safe Harbor
Statements pertaining to the future financial
and/or operating results, future growth in research, technology,
clinical development, and potential opportunities for Microbot
Medical Inc. and its subsidiaries, along with other statements
about the future expectations, beliefs, goals, plans, or prospects
expressed by management, constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995 and the Federal securities laws. Any statements that are
not historical fact (including, but not limited to statements that
contain words such as “will,” “believes,” “plans,” “anticipates,”
“expects” and “estimates”) should also be considered to be
forward-looking statements. Forward-looking statements involve
risks and uncertainties, including, without limitation, market
conditions and the satisfaction of customary closing conditions,
risks inherent in the development and/or commercialization of
potential products, including LIBERTY, the outcome of its studies
to evaluate the SCS and other existing and future technologies,
uncertainty in the results of pre-clinical and clinical trials or
regulatory pathways and regulatory approvals, need and ability to
obtain future capital, and maintenance of intellectual property
rights. Additional information on risks facing Microbot Medical can
be found under the heading “Risk Factors” in Microbot Medical’s
periodic reports filed with the Securities and Exchange Commission
(SEC), which are or will be available on the SEC’s web site at
www.sec.gov. Microbot Medical disclaims any intent or obligation to
update these forward-looking statements, except as required by
law.
Investor Contact:
Michael PolyviouEVC Groupmpolyviou@evcgroup.com732-933-2754
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/b1cc4d81-cab8-4b7c-80de-8b9a45810faf
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Sep 2023 to Sep 2024